Skip to main content
. 2019 Nov 1;10:2516. doi: 10.3389/fimmu.2019.02516

Figure 1.

Figure 1

Timeline showing the number of haploidentical stem cell transplantation and advances in Peking University Institute of Hematology, 2000–2018. Haplo-SCT, haploidentical stem cell transplantation; G-CSF, granulocyte colony-stimulating factor; HLA, human leukocyte antigen; HM, hematological malignancies; MSDT, HLA-matched sibling donor transplantation; DLI, donor lymphocyte infusion; MUDT, HLA-matched unrelated donor transplantation; SAA, severe aplastic anemia; AML, acute myeloid leukemia; MRD, minimal residual disease; ALL, acute lymphoblastic leukemia; GVHD, graft-vs.-host disease. The red number indicates cumulative cases of patients who underwent haplo-SCT until December 31, 2018.